Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia von Stein, Eytan M., DiNardo, Courtney D., Pollyea, Daniel A., Fathi, Amir T., Roboz, Gail J., Altman, Jessica K., Stone, Richard M., DeAngelo, Daniel J., Levine, Ross L., Flinn, Ian W., Kantarjian, Hagop M., Collins, Robert, Patel, Manish R., Frankel, Arthur E., Stein, Anthony, Sekeres, Mikkael A., Swords, Ronan T., Medeiros, Bruno C., Willekens, Christophe, Vyas, Paresh, Tosolini, Alessandra, Xu, Qiang, Knight, Robert D., Yen, Katharine E., Agresta, Sam, de Botton, Stephane, Tallman, Martin S.

Volltext

Bringing biomechanics to ballet: A feasibility study using wearable technology during grand allegro von Swords, T., Rio, E., McClelland, J., Middleton, K., Mayes, S., Tessarin, B., Bryce, S.

Volltext

A Case of AML Characterized by a Novel t(4;15)(q31;q22) Translocation That Confers a Growth-Stimulatory Response to Retinoid-Based Therapy von Watts, Justin M, Perez, Aymee, Pereira, Lutecia, Fan, Yao-Shan, Brown, Geoffrey, Vega, Francisco, Petrie, Kevin, Swords, Ronan T, Zelent, Arthur

Volltext

KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study von Swords, Ronan T., MD, PhD, FRCPI, FRCPath, Greenberg, Peter L., MD, Wei, Andrew H., MBBS, PhD, Durrant, Simon, MBBS, MRCS, LRCP, FRCP, FRCPath, Advani, Anjali S., MD, Hertzberg, Mark S., MBBS, PhD, FRACP, FRCPA, Lewis, Ian D., MBBS, PhD, Rivera, Gabriel, MD, Gratzinger, Dita, MD, PhD, Fan, Alice C., MD, Felsher, Dean W., MD, PhD, Cortes, Jorge E., MD, Watts, Justin M., MD, Yarranton, Geoff T., PhD, Walling, Jackie M., MB, ChB, PhD, Lancet, Jeffrey E., MD

Volltext

Functional genomic landscape of acute myeloid leukaemia von Tyner, Jeffrey W., Tognon, Cristina E., Bottomly, Daniel, Wilmot, Beth, Kurtz, Stephen E., Savage, Samantha L., Long, Nicola, Schultz, Anna Reister, Traer, Elie, Abel, Melissa, Agarwal, Anupriya, Blucher, Aurora, Borate, Uma, Bryant, Jade, Burke, Russell, Carlos, Amy, Carpenter, Richie, Carroll, Joseph, Chang, Bill H., Coblentz, Cody, d’Almeida, Amanda, Cook, Rachel, Danilov, Alexey, Dao, Kim-Hien T., Degnin, Michie, Devine, Deirdre, Dibb, James, Edwards, David K., Eide, Christopher A., English, Isabel, Glover, Jason, Henson, Rachel, Ho, Hibery, Jemal, Abdusebur, Johnson, Kara, Johnson, Ryan, Junio, Brian, Kaempf, Andy, Leonard, Jessica, Lin, Chenwei, Liu, Selina Qiuying, Lo, Pierrette, Loriaux, Marc M., Luty, Samuel, Macey, Tara, MacManiman, Jason, Martinez, Jacqueline, Mori, Motomi, Nelson, Dylan, Nichols, Ceilidh, Peters, Jill, Ramsdill, Justin, Rofelty, Angela, Schuff, Robert, Searles, Robert, Segerdell, Erik, Smith, Rebecca L., Spurgeon, Stephen E., Sweeney, Tyler, Thapa, Aashis, Visser, Corinne, Wagner, Jake, Watanabe-Smith, Kevin, Werth, Kristen, Wolf, Joelle, White, Libbey, Yates, Amy, Zhang, Haijiao, Cogle, Christopher R., Collins, Robert H., Connolly, Denise C., Deininger, Michael W., Drusbosky, Leylah, Hourigan, Christopher S., Jordan, Craig T., Kropf, Patricia, Lin, Tara L., Martinez, Micaela E., Medeiros, Bruno C., Pallapati, Rachel R., Pollyea, Daniel A., Swords, Ronan T., Watts, Justin M., Weir, Scott J., Wiest, David L., Winters, Ryan M., McWeeney, Shannon K., Druker, Brian J.

Volltext

Pevonedistat (MLN4924), a First‐in‐Class NEDD8‐activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study von Swords, Ronan T., Erba, Harry P., DeAngelo, Daniel J., Bixby, Dale L., Altman, Jessica K., Maris, Michael, Hua, Zhaowei, Blakemore, Stephen J., Faessel, Hélène, Sedarati, Farhad, Dezube, Bruce J., Giles, Francis J., Medeiros, Bruno C.

Volltext

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML von Swords, Ronan T., Coutre, Steven, Maris, Michael B., Zeidner, Joshua F., Foran, James M., Cruz, Jose, Erba, Harry P., Berdeja, Jesus G., Tam, Wayne, Vardhanabhuti, Saran, Pawlikowska-Dobler, Iwona, Faessel, Hélène M., Dash, Ajeeta B., Sedarati, Farhad, Dezube, Bruce J., Faller, Douglas V., Savona, Michael R.

Volltext

Integrative analysis of drug response and clinical outcome in acute myeloid leukemia von Bottomly, Daniel, Long, Nicola, Schultz, Anna Reister, Kurtz, Stephen E., Tognon, Cristina E., Johnson, Kara, Abel, Melissa, Agarwal, Anupriya, Avaylon, Sammantha, Benton, Erik, Blucher, Aurora, Borate, Uma, Braun, Theodore P., Brown, Jordana, Bryant, Jade, Burke, Russell, Carlos, Amy, Chang, Bill H., Cho, Hyun Jun, Christy, Stephen, Coblentz, Cody, Cohen, Aaron M., d’Almeida, Amanda, Cook, Rachel, Danilov, Alexey, Dao, Kim-Hien T., Degnin, Michie, Dibb, James, Eide, Christopher A., English, Isabel, Hagler, Stuart, Harrelson, Heath, Henson, Rachel, Ho, Hibery, Joshi, Sunil K., Junio, Brian, Kaempf, Andy, Kosaka, Yoko, Laderas, Ted, Lawhead, Matt, Lee, Hyunjung, Leonard, Jessica T., Lin, Chenwei, Lind, Evan F., Liu, Selina Qiuying, Lo, Pierrette, Loriaux, Marc M., Luty, Samuel, Maxson, Julia E., Macey, Tara, Martinez, Jacqueline, Minnier, Jessica, Monteblanco, Andrea, Mori, Motomi, Morrow, Quinlan, Nelson, Dylan, Ramsdill, Justin, Rofelty, Angela, Rogers, Alexandra, Romine, Kyle A., Ryabinin, Peter, Saultz, Jennifer N., Sampson, David A., Savage, Samantha L., Schuff, Robert, Searles, Robert, Smith, Rebecca L., Spurgeon, Stephen E., Sweeney, Tyler, Swords, Ronan T., Thapa, Aashis, Thiel-Klare, Karina, Traer, Elie, Wagner, Jake, Wilmot, Beth, Wolf, Joelle, Wu, Guanming, Yates, Amy, Zhang, Haijiao, Cogle, Christopher R., Collins, Robert H., Deininger, Michael W., Hourigan, Christopher S., Jordan, Craig T., Lin, Tara L., Martinez, Micaela E., Pallapati, Rachel R., Pollyea, Daniel A., Pomicter, Anthony D., Watts, Justin M., Weir, Scott J., Druker, Brian J., McWeeney, Shannon K., Tyner, Jeffrey W.

Volltext

Very late relapse of AML after allogeneic hematopoietic cell transplantation is often extramedullary von Watts, J M, Wang, X V, Swords, R T, Paietta, E, Douer, D, Lugar, S M, Fernandez, H F, Rowe, J M, Lazarus, H M, Tallman, M S, Litzow, M R

Volltext

Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies von Tayari, Mina M, Santos, Helena G Dos, Kwon, Deukwoo, Bradley, Terrence J, Thomassen, Amber, Chen, Charles, Dinh, Yvonne, Perez, Aymee, Zelent, Arthur, Morey, Lluis, Cimmino, Luisa, Shiekhattar, Ramin, Swords, Ronan T, Watts, Justin M

Volltext

Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies von Kurtz, Stephen E, Eide, Christopher A, Kaempf, Andy, Khanna, Vishesh, Savage, Samantha L, Rofelty, Angela, English, Isabel, Ho, Hibery, Pandya, Ravi, Bolosky, William J, Poon, Hoifung, Deininger, Michael W, Collins, Robert, Swords, Ronan T, Watts, Justin, Pollyea, Daniel A, Medeiros, Bruno C, Traer, Elie, Tognon, Cristina E, Mori, Motomi, Druker, Brian J, Tyner, Jeffrey W

Volltext

Corrigendum to “KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1... von Swords, Ronan T., MD, PhD, Greenberg, Peter L., MD, Wei, Andrew H., MBBS, PhD, Durrant, Simon, MBBS, Advani, Anjali S., MD, Hertzberg, Mark S., MBBS, PhD, Lewis, Ian D., MBBS, PhD, Rivera, Gabriel, MD, Gratzinger, Dita, MD, PhD, Fan, Alice C., MD, Felsher, Dean W., MD, PhD, Cortes, Jorge E., MD, Watts, Justin M., MD, Yarranton, Geoff T., PhD, Walling, Jackie M., MB, ChB, PhD, Lancet, Jeffrey E., MD

Volltext

Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia von Swords, Ronan T., Kelly, Kevin R., Smith, Peter G., Garnsey, James J., Mahalingam, Devalingam, Medina, Ernest, Oberheu, Kelli, Padmanabhan, Swaminathan, O'Dwyer, Michael, Nawrocki, Steffan T., Giles, Francis J., Carew, Jennifer S.

Volltext

A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival von Garcia, Jacqueline S., Swords, Ronan T., Roboz, Gail J., Jacoby, Meagan A., Garcia-Manero, Guillermo, Hong, Wan-Jen, Yang, Xiaoqing, Zhou, Ying, Platzbecker, Uwe, Steensma, David P., Wolff, Johannes E., Fenaux, Pierre

Volltext

Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study von Swords, Ronan T., Azzam, Diana, Al-Ali, Hassan, Lohse, Ines, Volmar, Claude-Henry, Watts, Justin M., Perez, Aymee, Rodriguez, Ana, Vargas, Fernando, Elias, Roy, Vega, Francisco, Zelent, Arthur, Brothers, Shaun P., Abbasi, Taher, Trent, Jonathan, Rangwala, Shaukat, Deutsch, Yehuda, Conneally, Eibhlin, Drusbosky, Leylah, Cogle, Christopher R., Wahlestedt, Claes

Volltext

Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial von Duong, Vu H., Ruppert, Amy S., Mims, Alice S., Borate, Uma, Stein, Eytan M., Baer, Maria R., Stock, Wendy, Kovacsovics, Tibor, Blum, William, Arellano, Martha L., Schiller, Gary J., Olin, Rebecca L., Foran, James M., Litzow, Mark R., Lin, Tara L., Patel, Prapti A., Foster, Matthew C., Redner, Robert L., Al‐Mansour, Zeina, Cogle, Christopher R., Swords, Ronan T., Collins, Robert H., Vergilio, Jo‐Anne, Heerema, Nyla A., Rosenberg, Leonard, Yocum, Ashley O., Marcus, Sonja, Chen, Timothy, Druggan, Franchesca, Stefanos, Mona, Gana, Theophilus J., Shoben, Abigail B., Druker, Brian J., Burd, Amy, Byrd, John C., Levine, Ross L., Boyiadzis, Michael M.

Volltext

Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study von DiNardo, Courtney D., De Botton, Stephane, Stein, Eytan M., Roboz, Gail J., Mims, Alice S., Pollyea, Daniel A., Swords, Ronan T., Altman, Jessica K., Collins, Robert H., Mannis, Gabriel N., Uy, Geoffrey L., Donnellan, Will, Pigneux, Arnaud, Fathi, Amir T., Stein, Anthony S., Erba, Harry P., Prince, Gabrielle T., Foran, James M., Traer, Elie, Stuart, Robert K., Arellano, Martha L., Slack, James L., Sekeres, Mikkael A., Yen, Katharine, Kapsalis, Stephanie M., Liu, Hua, Goldwasser, Meredith, Agresta, Sam, Attar, Eyal C., Tallman, Martin S., Stone, Richard M., Kantarjian, Hagop M.

Volltext

A new approach to the treatment of acute myeloid leukaemia targeting the receptor for growth hormone‐releasing hormone von Jimenez, Joaquin J., DelCanto, Gina M., Popovics, Petra, Perez, Aymee, Vila Granda, Ailin, Vidaurre, Irving, Cai, Ren‐Zhi, Rick, Ferenc G., Swords, Ronan T., Schally, Andrew V.

Volltext

The NEDD8-activating enzyme inhibitor pevonedistat activates the eIF2α and mTOR pathways inducing UPR-mediated cell death in acute lymphoblastic leukemia von Leclerc, Gilles M, Zheng, Shuhua, Leclerc, Guy J, DeSalvo, Joanna, Swords, Ronan T, Barredo, Julio C

Volltext

Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia von Chapman, Jennifer, Geyer, Julia T, Khanlari, Mahsa, Moul, Adrienne, Casas, Carmen, Connor, Scot T, Fan, Yao-Shan, Watts, Justin M, Swords, Ronan T, Vega, Francisco, Orazi, Attilio

Volltext